Patient Insight and Treatment Expectations in Erectile Dysfunction - European Medical Journal

Patient Insight and Treatment Expectations in Erectile Dysfunction

Reproductive Health
Download PDF
*Hartmut Porst

Hartmut Porst is an Investigator, Speaker, and Consultant for Auxilium, Eli Lilly, Menarini/Berlin Chemie, and Sanofi.


Medical writing assistance was provided by Dr Caroline Charles (Scilink Medical Writing, Biarritz, France).

EMJ. ;1[2]:34-41. DOI/10.33590/emj/10312334.
Erectile dysfunction (ED), patient preference, treatment adherence, quality of life, sildenafil, vardenafil, tadalafil, avanafil, oral phosphodiesterase type 5 (PDE5) inhibitors

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.


In the literature, a strong preference towards pharmacological management with oral phosphodiesterase type 5 (PDE5) inhibitors has been demonstrated in men with erectile dysfunction (ED) versus other methods. However, following pharmacological management, a large proportion of men with ED discontinue treatment prematurely. Therefore, a better understanding of the expectations from, and demands on modern ED management from both the patients and their partners is needed in order to identify factors that may improve outcomes, patient adherence, and patient satisfaction with therapy. Thus, we will present new findings on patient and partner satisfaction and preferences, and discuss how the current pharmacological armamentarium can answer these needs.

Please view the full content in the pdf above.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now